Author: Scott Welch
Republicans and Democrats have a narrow opening to cut big deals on drug pricing and surprise medical bills and address two key concerns of voters — just in time for 2020 electoral politics to drive them apart.
Drugmakers including Bristol-Myers Squibb Co., Gilead Sciences Inc., and Biogen Inc. hiked U.S. list prices on more than 50 drugs on Wednesday, bringing total New Year’s Day drug price increases to more than 250, according to data analyzed by healthcare research firm 3 Axis Advisors.
In an election year when nobody expects Congress to pass meaningful legislation, lawmakers are feeling strong political pressure to reach a deal on at least one main voter priority: lowering drug prices.
Sutter Health will pay $575 million to settle a closely watched antitrust case filed by California Attorney General Xavier Becerra, whose office had accused the nonprofit health care giant of using its market dominance in Northern California to illegally drive up prices.
The Silver State Health Insurance Exchange announced Monday that they have extended the deadline of Open Enrollment for consumers who started the application process on or before the Dec. 15 deadline.
A three-judge panel at the 5th U.S. Circuit Court of Appeals kept suspense about the entire Affordable Care Act legislative package alive this week by ruling that the ACA’s individual coverage mandate provision is an unconstitutional requirement to buy a private product, but that it’s not clear whether killing the provision really kills all of the ACA.
A federal appeals court on Wednesday struck down Obamacare’s individual mandate in a decision that immediately thrusts the health care law to the forefront of the 2020 elections.
Elizabeth Warren told members of Nevada’s powerful casino workers’ union Monday that she wants to see their strong health care plans replicated around the country but the Democratic presidential candidate sidestepped the details of her Medicare for All proposal and how it might affect the union.
Surprise billing legislation suddenly stalled. Like “Medicare for all,” the proposal would have lowered the pay of some physicians.
The Trump administration is laying the groundwork to allow some cheaper prescription drugs to be imported from Canada.